NTLA Stock: Price, Earnings History and SEC Filings
Intellia Therapeutics, Inc. (NTLA) last traded at $12.47, down 5.74% on the latest session and up 3.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.80 against an analyst estimate of $-0.80, a beat of 0.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NTLA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.80 | $-0.80 | +0.00% |
| Mar 2026 | May 11, 2026 | $-0.81 | $-0.92 | +11.96% |
| Dec 2025 | Feb 26, 2026 | $-0.83 | $-0.99 | +16.16% |
| Sep 2025 | Nov 6, 2025 | $-0.92 | $-1.02 | +9.80% |
NTLA beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How NTLA reacts to earnings
Across its last 8 earnings releases, NTLA moved 6.3% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | +2.46% |
| 2026-05-11 | Before open | +2.34% |
| 2026-04-30 | After close | -1.63% |
| 2026-02-26 | Before open | +6.41% |
| 2025-11-06 | After close | -22.73% |
| 2025-08-07 | Before open | +0.79% |
| 2025-05-08 | Before open | +13.58% |
| 2025-02-27 | Before open | +0.56% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
NTLA financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $68M | -$413M | -$396M | -609.9% | $-3.81 |
| 2024 | $58M | -$519M | -$355M | -896.8% | $-5.25 |
| 2023 | $36M | -$481M | -$408M | -1326.5% | $-5.42 |
| 2022 | $52M | -$474M | -$347M | -909.8% | $-6.16 |
| 2021 | $33M | -$268M | -$238M | -810.5% | $-3.78 |
| 2020 | $58M | -$134M | -$53M | -231.5% | $-2.40 |
| 2019 | $43M | -$474M | -$110M | -1100.1% | – |
| 2018 | $30M | -$85M | -$68M | -280.4% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for NTLA
- 8-K · Sep 8, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Sep 4, 2026Material agreement, New financial obligation, Regulation FD disclosure
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 15, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Jun 10, 2026Shareholder vote
- 10-Q · May 11, 2026
- 8-K · May 11, 2026Results of operations, Financial statements and exhibits
- 8-K · Apr 30, 2026Material agreement, Results of operations, Financial statements and exhibits
- DEF 14A · Apr 30, 2026
Insider filing activity
NTLA insiders filed 3 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
NTLA news
- Exelixis (EXEL) Surpasses Q3 Earnings and Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026Oct 29, 2026 · finance.yahoo.com
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Oct 28, 2026 · finance.yahoo.com
- Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue EstimatesOct 28, 2026 · finance.yahoo.com
- Has The Story Under Krystal Biotech Stock Run Out?Oct 28, 2026 · trefis.com
- The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking TherapeuticsOct 21, 2026 · finance.yahoo.com
- 4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowOct 20, 2026 · finance.yahoo.com
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (NTLA) is a US-listed public company on Nasdaq. The SEC classifies its business as In Vitro & In Vivo Diagnostic Substances. It is incorporated in DE. Its fiscal year ends in December.